Welcome to our dedicated page for OptimizeRx Corporation news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx Corporation stock.
OptimizeRx Corporation (NASDAQ: OPRX) is a leading provider in the healthcare technology sector, offering digital health messaging solutions that enhance communication between pharmaceutical companies, healthcare providers, and patients. OptimizeRx specializes in the integration of electronic health records (EHR) to distribute financial assistance, educational materials, and clinical information directly at the point of care.
The company leverages its proprietary SampleMD and eCoupon technologies to expand the distribution of patient savings and support materials within the e-prescribing workflows of over 300,000 healthcare providers. These platforms enable healthcare providers to deliver real-time financial assistance and support to patients, thereby improving medication adherence and affordability.
OptimizeRx offers a range of products, including Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. These solutions aim to help patients start and stay on their prescribed treatments while providing pharmaceutical companies with efficient ways to increase brand awareness and adherence.
Recently, OptimizeRx has undergone significant leadership changes. Gus Halas retired as Chairperson of the Board, succeeded by Lynn O’Connor Vos, a seasoned executive with extensive experience in healthcare IT and life sciences. Additionally, Catherine M. Klema was appointed to the Board, bringing her expertise in strategy, finance, and governance.
Financially, OptimizeRx is in a robust position. The company's revenue for FY2023 is estimated to exceed $68-$70 million, with adjusted EBITDA ranging between $3-$4 million. For 2024, the company anticipates revenue of at least $100 million due to a revised gross-to-net accounting treatment for certain revenue streams from its recent acquisition of Medicx Health.
The mission of OptimizeRx is to empower the healthcare community through innovative, tech-enabled communication solutions that improve patient care. By connecting over 60% of U.S. healthcare providers and millions of patients through its digital point-of-care network, OptimizeRx continues to deliver significant value to patients, healthcare professionals, and investors.
For more information, visit www.optimizerx.com
OptimizeRx Corp (Nasdaq: OPRX) announced that its Senior VP of Corporate Finance, Andy D'Silva, will participate in the 34th Annual ROTH Conference from March 13-15, 2022, in Dana Point, CA. D'Silva will engage in one-on-one and small group meetings with investors on March 14-15. The conference includes discussions on various growth sectors, featuring approximately 400 companies. OptimizeRx connects over 60% of U.S. healthcare providers, facilitating patient engagement and therapy adherence through its technology platform.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 24% increase in Q4 2021 revenues, reaching $20.3 million, with a gross profit margin of 61%. Full-year revenue rose 42% to $61.3 million. The company achieved a net income of $0.6 million in Q4, down from $1.4 million in the previous year, while non-GAAP net income improved to $4.0 million. The firm anticipates 2022 revenue between $80 million and $85 million, reflecting growth between 31% and 39%.
OptimizeRx Corp (Nasdaq: OPRX) reported preliminary financial results for Q4 2021, anticipating revenues of approximately $20.3 million, marking a 42% increase year-over-year. The company achieved a GAAP net income of $0.6 million and a record adjusted EBITDA of $4.0 million. As part of its growth strategy, OptimizeRx introduced new KPIs focused on customer penetration within the top pharmaceutical manufacturers and aims for 2022 revenues between $80 million to $85 million, projecting 31% to 39% growth.
OptimizeRx Corp. (Nasdaq: OPRX) will conduct a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its fourth-quarter and full-year financial results for 2021. The call will include a Q&A session following the management's presentation. Interested parties can access the conference via toll-free and international numbers or through a webcast link. A replay will be available for 12 months on the OptimizeRx investor website. The Company focuses on digital health solutions, connecting over 60% of U.S. healthcare providers and millions of patients.
OptimizeRx Corp (Nasdaq: OPRX) announced that CEO Will Febbo will participate in Bank of America's Annual HCIT and Digital Health Conference on February 23, 2022. He will speak on a panel titled 'Tech-Enabled Rx Solutions' from 11:15 AM ET to 12:00 PM ET. The event will attract healthcare executives and investors focused on digital health and technology solutions.
OptimizeRx is a leader in point-of-care technology, connecting over 60% of U.S. healthcare providers and millions of patients to improve therapy adherence.
OptimizeRx Corp (Nasdaq: OPRX) announced that vice president of data product, Mike Rousselle, has been named to MM+M’s 40 Under 40 List, highlighting his significant contributions to healthcare marketing. Rousselle is known for leveraging AI and ML to enhance patient-physician communication through the utilization of real-world data. This recognition not only reflects Rousselle's innovative leadership but also reinforces OptimizeRx's commitment to improving patient outcomes by connecting life sciences organizations with healthcare providers effectively.
OptimizeRx Corp (Nasdaq: OPRX), a leading health technology provider, announced participation in two key conferences: the 11th Annual SVB Leerink Global Healthcare Conference on February 17 and the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15. Will Febbo, CEO, will feature in a fireside chat at the SVB event, while the company will present at the BTIG conference. The leadership team will also be available for virtual one-on-one meetings to discuss their innovative point-of-care technology solutions.
OptimizeRx Corp (Nasdaq: OPRX) announced its CEO, Will Febbo, will moderate a panel on 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care' at the LifeSci Partners Corporate Access Event from January 5-7, 2022. The panel will occur on January 6, 2022, at 8:30 AM ET. Other companies participating include Augmedix, DarioHealth, and LifeMD. Interested viewers must register in advance to access the panel. OptimizeRx's technology solutions aim to help patients start and stay on therapy, connecting over 60% of U.S. healthcare providers.
FAQ
What is the current stock price of OptimizeRx Corporation (OPRX)?
What is the market cap of OptimizeRx Corporation (OPRX)?
What does OptimizeRx Corporation do?
What are the main products offered by OptimizeRx?
How does OptimizeRx help patients?
Who is the current Chairperson of OptimizeRx?
What recent changes have occurred in OptimizeRx's leadership?
What are OptimizeRx's financial expectations for 2024?
How widely is OptimizeRx's technology adopted?
What is SampleMD?
Where can I find more information about OptimizeRx?
What is the mission of OptimizeRx?
